Skip navigation

FEATURED SLIDESHOW


Current DateTime: 10:34:55 09 Feb 2012
LinksList Documentid: 44892814
  • Cramer's Best Dividend Picks

      In chaotic and difficult market environments, Jim Cramer recommends investors seek the protection of stocks with serious dividends.


Text SMS AlertGet stock and market information from Mad Money's Jim Cramer sent to your mobile phone.
Road Rules
Road Rules Video Gallery
Investing can be confusing. Luckily, Cramer has mapped out some road rules for all you Home Gamers trying to navigate the jungle that is Wall Street. Think of it as "Mad Money 101" –- some fundamental advice to keep in mind as you play the market. Whether you're a first time investor or a seasoned financier, it's always good to remember the basics.

Not Just Breast Implants Anymore

Published: Monday, 28 Jan 2008 | 11:31 AM ET
Text Size
By: Carlo Dellaverson
Web Producer

As Cramer is fond of saying, the wheels of capitalism are greased by our collective desire to look younger and more beautiful. That’s why he has long been recommending Allergan [AGN  Loading...      ()   ], the cosmetic behemoth behind Botox and silicon breast implants that he thinks is about as recession-proof as they come.

But now there’s an even better reason to buy Allergan: it could save lives. A front-page article in the New York Times this week pointed to a new study that found weight-loss surgery can help cure Type 2 diabetes in obese patients. The surgery, known as gastric banding, is basically a less risky and less expensive form of stomach stapling where a band is placed around the stomach to make it smaller and causes the patient to eat less.

Allergan is on the frontlines of this procedure with its own proprietary gastric banding system known as the LAP-BAND. This will be the future of the company, Cramer said. Along with the 20 million Americans with diabetes, Allergan could be the winner if this takes off. And already resulting in complete remission among 73% of patients, it sure seems like it will.

The stock is down 7% from its high, marking a good entry point, according to Cramer. He would put on half a position before the earnings report on Jan. 30, and half after. The bottom line? Allergan is no longer just fake breasts and tight skin. Now it could help cure a life-threatening disease.


Questions for Cramer?

Questions, comments, suggestions for the Mad Money website?

© 2012 CNBC, Inc. All Rights Reserved


Current DateTime: 11:43:35 09 Feb 2012
LinksList Documentid: 29778428

Current DateTime: 11:56:47 09 Feb 2012
LinksList Documentid: 29779196

Current DateTime: 10:08:28 09 Feb 2012
LinksList Documentid: 29779197

Current DateTime: 01:22:57 09 Feb 2012
LinksList Documentid: 29779199
CNBCCNBC
About CNBC  |  Site Map  |  Video Reprints   |  Advertise  |  Help  |  Contact
Privacy Policy  |     |  Terms of Service  |  Independent Programming Report
  Data is a real-time snapshot  *Data is delayed at least 15 minutes
Global Business and Financial News, Stock Quotes, and Market Data and Analysis

© 2012 CNBC LLC.  All Rights Reserved.
A Division of NBCUniversal
Thomson ReutersThomson Reuters